A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive
Yoshihiko Kubo, MD, PhD
Advertisement
Articles by Yoshihiko Kubo, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Data Readouts to Watch at the 2026 ASCO Annual Meeting
2
Alpha DaRT Elicits 100% Local Disease Control in Pancreatic Cancer
3
Outlining Exercise as a “Biologically Interventional Therapy” for Cancer
4
Navigating The Dynamic Landscape of Stem Cell Transplantation
5